Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1Endometrial Neoplasms 1

Interventions

Paclitaxel 42Carboplatin 35pembrolizumab 25Surveys and Questionnaires 23Letrozole 15Radiotherapy 14Megestrol Acetate 14Blood Specimen Collection 14Bevacizumab 13olaparib 12Metformin 12dostarlimab 10Indocyanine Green 10durvalumab 9Observation 9Medroxyprogesterone Acetate 9Cisplatin 9lenvatinib 8atezolizumab 8Early Intervention, Educational 8Counseling 8niraparib 7Sentinel Lymph Node Biopsy 7Radiation 7Methods 7Magnetic Resonance Spectroscopy 7Lymph Node Excision 7Hysterectomy 7Everolimus 7abemaciclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Endometrial Neoplasms × trastuzumab duocarmazine × Clear all
NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

QuantumLeap Healthcare Collaborative

Phase 1 Withdrawn
BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡